Intro
Tirzepatide is a prescription medication used to treat type 2 diabetes and, more recently, chronic weight management.
It belongs to a newer class of drugs that act on two hormone receptors simultaneously, distinguishing it from earlier single-action GLP-1 medications. Clinical trials have shown substantial effects on blood sugar control and body weight in eligible patients.
Interest in tirzepatide has grown quickly — both within mainstream medicine and in online communities focused on metabolic health and longevity. That interest often outruns the available clinical nuance, which this guide attempts to address.
Key Points
- Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates two hormone pathways, not just one
- It is approved for type 2 diabetes and for chronic weight management in adults who meet clinical criteria
- Clinical trials have reported average weight reductions of roughly 15–22% in people with obesity — larger than most previously available medications
- Side effects are primarily gastrointestinal and are consistent with the broader class of incretin-based drugs
- Serious contraindications include a personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Long-term cardiovascular outcome data are still emerging
- A significant counterfeit and unregulated compounded market exists; product quality from informal sources cannot be assumed
What Tirzepatide Is
Tirzepatide is a synthetic peptide drug developed by Eli Lilly. It was approved by the US Food and Drug Administration (FDA) in May 2022 under the brand name Mounjaro for the treatment of type 2 diabetes, and in November 2023 under the brand name Zepbound specifically for chronic weight management.
It is administered as a once-weekly subcutaneous injection, available in multiple dose strengths to allow gradual titration.
This guide focuses on the generic compound (tirzepatide) rather than any specific brand. Brand names are noted here for context only.
How It Works
Dual receptor activity
Tirzepatide activates two receptors:
- GLP-1 (glucagon-like peptide-1) receptors — which regulate insulin secretion, reduce glucagon, slow gastric emptying, and signal satiety to the brain
- GIP (glucose-dependent insulinotropic polypeptide) receptors — which also influence insulin and glucagon secretion, and may affect fat metabolism and energy balance
Earlier GLP-1 drugs (such as semaglutide and liraglutide) act only on GLP-1 receptors. Tirzepatide’s dual mechanism is thought to contribute to its larger average effect on body weight and glycaemic control in clinical trials, though the precise clinical significance of GIP activation is still being studied.
Effects on metabolism
Together, these receptor effects produce:
- increased insulin secretion in a glucose-dependent manner
- reduced glucagon release
- slowed gastric emptying (food moves more slowly through the stomach)
- reduced appetite and food intake
- improvements in insulin sensitivity
These mechanisms translate into lower blood glucose levels and, over time, meaningful reductions in body weight.
Approved Uses and Why It Gets Attention
Approved indications
Tirzepatide is currently FDA-approved for:
- Type 2 diabetes — as an adjunct to diet and exercise to improve glycaemic control in adults
- Chronic weight management — for adults with a body mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related condition (such as hypertension, dyslipidaemia, or type 2 diabetes)
These approvals are based on randomised controlled trial data from the SURPASS programme (diabetes) and the SURMOUNT programme (weight management).
Why it receives disproportionate attention
Several factors have contributed to heightened public interest:
- Weight loss results in clinical trials were larger than for most previously approved medications
- Online communities and some clinics began discussing tirzepatide extensively before and after regulatory approval
- Supply shortages led to widespread compounding, which in turn expanded informal access
- The drug is sometimes grouped with semaglutide under the umbrella of “Ozempic-type drugs,” though the two are pharmacologically distinct
This guide tries to separate what is established from what is still evolving or contested.
Benefits and Evidence
Clinical evidence for tirzepatide comes primarily from:
- The SURPASS clinical trial programme (six trials in type 2 diabetes patients)
- The SURMOUNT clinical trial programme (trials in people with obesity, with and without diabetes)
Glycaemic control (diabetes)
In the SURPASS trials, tirzepatide produced larger reductions in HbA1c than comparator treatments including semaglutide, insulin degludec, and dulaglutide in head-to-head comparisons. Reductions of 1.5–2.4 percentage points in HbA1c were reported across dose levels.
Body weight (weight management)
In SURMOUNT-1 — a 72-week trial in adults with obesity but without diabetes — participants on the highest dose of tirzepatide lost an average of approximately 22% of body weight, compared with around 2% in the placebo group.
These are average figures from a controlled trial setting with close clinical support. Real-world outcomes vary and depend on adherence, dose reached, individual response, and lifestyle factors.
Cardiovascular and other outcomes
Long-term cardiovascular outcome data for tirzepatide are still accumulating. At the time of writing, tirzepatide does not yet have the same body of established cardiovascular evidence as semaglutide, which has data from the SELECT trial (a large cardiovascular outcomes trial in people with obesity but without diabetes). Cardiovascular trials for tirzepatide are ongoing, and results should be reviewed as they emerge.
Claims about tirzepatide specifically reducing cardiovascular risk should be evaluated carefully against the current state of the evidence.
Muscle preservation and body composition
Some clinical data suggest tirzepatide may preserve a higher proportion of lean mass during weight loss than seen in historical comparisons. This remains an active area of study. The general risk of lean mass loss during any significant caloric deficit applies; structured resistance training and adequate protein intake remain important for patients on this medication.
See Muscle Preservation on GLP-1 Medications for practical guidance on this topic.
Risks and Side Effects
Common side effects
Most adverse effects are gastrointestinal and are more common during dose escalation:
- nausea
- vomiting
- diarrhoea
- constipation
- abdominal discomfort or bloating
- reduced appetite
These typically lessen after the first few weeks at a given dose. Gradual dose titration is standard practice to improve tolerability.
Less common but notable
- Gallstones (cholelithiasis) — rapid weight loss increases gallstone risk across weight-loss treatments, not only with tirzepatide
- Gastroparesis-like symptoms — persistent severe slowing of stomach emptying in some patients
- Pancreatitis — rare; patients with a history of pancreatitis should discuss this with their prescriber
- Hair shedding (telogen effluvium) — associated with significant caloric restriction rather than the drug directly
- Injection site reactions — mild and common
Serious warnings
Tirzepatide carries a boxed warning regarding thyroid C-cell tumours, based on animal studies. The clinical relevance in humans is not established, but the drug is contraindicated in certain individuals as a precaution (see below).
Contraindications and Precautions
Contraindications
Tirzepatide is contraindicated in people with:
- a personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- known hypersensitivity to tirzepatide or any component of the formulation
Precautions and considerations
- Pregnancy: tirzepatide is not recommended during pregnancy; patients should use effective contraception and discontinue the medication prior to conception
- Pancreatitis history: use with caution and discuss with a prescriber
- Renal or hepatic impairment: may require monitoring; dose adjustment not generally required for mild-to-moderate impairment based on current data, but severe cases warrant clinical assessment
- Diabetic retinopathy: rapid improvements in blood sugar control can temporarily worsen diabetic retinopathy in some patients; ophthalmological monitoring may be appropriate
- Heart rate: some patients experience a mild increase in resting heart rate; clinical significance in most patients is uncertain
- Interactions: slowed gastric emptying can affect the absorption of oral medications; patients on narrow therapeutic index drugs should discuss timing and monitoring with their prescriber
Regulation and Product Quality
Regulatory status
Tirzepatide is a prescription-only medication in most jurisdictions. In the United States, both Mounjaro and Zepbound are FDA-approved and classified as brand-name biologics. Access requires a valid prescription from a licensed prescriber.
Compounded tirzepatide
During periods of shortage (primarily 2022–2024), compounding pharmacies in the US were permitted to prepare tirzepatide-containing preparations under FDA shortage exemptions. The FDA removed tirzepatide from its shortage list in late 2024, after which the legal basis for compounding changed significantly. Regulations in this area continue to evolve.
Compounded preparations may not have the same formulation, potency, sterility standards, or inactive ingredients as the approved product. Patients who obtained or are considering compounded tirzepatide should discuss this with a prescriber and verify the regulatory status of their source.
Informal and unregulated markets
A market for tirzepatide purchased outside of formal prescribing channels — including online pharmacies, overseas suppliers, and peptide research vendors — exists in many countries. Products sold through these channels carry meaningful risks:
- undisclosed or incorrect active ingredient
- incorrect dosing or concentration
- contamination or substandard sterility
- no quality control or batch testing
Patients cannot reliably verify the contents of products from informal sources. This applies whether the product is labelled as “research use only” or sold as a finished injectable preparation.
FAQ
Q: How is tirzepatide different from semaglutide? A: Semaglutide activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors — a dual mechanism that may account for its larger average weight loss in clinical trials. The two drugs are not interchangeable, and head-to-head comparisons show tirzepatide producing greater average weight reduction, though individual responses vary.
Q: Is tirzepatide approved for weight loss? A: Yes. Tirzepatide (as Zepbound) was FDA-approved in November 2023 for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. This is a specific indication with defined prescribing criteria, not a general use.
Q: How much weight does tirzepatide cause on average? A: In the SURMOUNT-1 trial, participants on the highest dose lost an average of approximately 22% of body weight over 72 weeks. This is a trial average from a controlled setting; real-world results vary. Some patients lose substantially less; some lose more.
Q: Is tirzepatide safe long-term? A: The available trial data extend to around 72–104 weeks for most studies. Longer-term safety data are being collected but are not yet as extensive as for some older drug classes. It is studied in large controlled trials with close monitoring, which differs from informal use outside clinical supervision.
Q: Can tirzepatide be used by people without diabetes? A: Yes — the weight management indication (Zepbound) covers people without diabetes who meet BMI criteria. The diabetes indication (Mounjaro) is for type 2 diabetes specifically.
Q: What happens when tirzepatide is stopped? A: Clinical data suggest that weight regain occurs when tirzepatide is discontinued, consistent with other GLP-1-class drugs. The drug appears to manage rather than resolve the underlying condition. Stopping without a plan for lifestyle maintenance is associated with partial or substantial weight regain.
Q: Is compounded tirzepatide the same as the brand-name version? A: Compounded preparations may differ in formulation, potency, or purity. They have not undergone the same regulatory review as approved products. The FDA’s position on compounded tirzepatide has changed as supply has normalised; patients should verify the current regulatory status with a prescriber.
Q: What is the thyroid cancer warning about? A: Animal studies found that GLP-1 receptor agonists caused thyroid C-cell tumours in rodents at certain doses. It is not established whether this risk applies to humans. As a precaution, tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Patients with thyroid concerns should discuss this with their prescriber.